Dr. El-Deiry on Liquid Vs Tissue Biopsies

Wafik El-Deiry, MD, PhD, FACP
Published: Tuesday, Jul 03, 2018



Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses the advantages of liquid biopsies over tissue biopsies. This was a hot debate at the 2018 ASCO Annual Meeting.

El-Deiry says that liquid biopsies do a better job of capturing the signature of any part of a tumor throughout the body. By their nature, liquid biopsies can easily detect tumor heterogeneity, which is something that a tissue biopsy cannot do for one specific part of the body. A common argument, El-Deiry adds, is that liquid biopsies have not yet been clinically proven in terms of benefitting treatment of patients. While he says this will take years to do, El-Deiry believes liquid biopsies will eventually become part of routine clinical practice.

Liquid biopsies are most commonly used for detecting molecular mutations in patients with non-small cell lung cancer. (NSCLC).


Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses the advantages of liquid biopsies over tissue biopsies. This was a hot debate at the 2018 ASCO Annual Meeting.

El-Deiry says that liquid biopsies do a better job of capturing the signature of any part of a tumor throughout the body. By their nature, liquid biopsies can easily detect tumor heterogeneity, which is something that a tissue biopsy cannot do for one specific part of the body. A common argument, El-Deiry adds, is that liquid biopsies have not yet been clinically proven in terms of benefitting treatment of patients. While he says this will take years to do, El-Deiry believes liquid biopsies will eventually become part of routine clinical practice.

Liquid biopsies are most commonly used for detecting molecular mutations in patients with non-small cell lung cancer. (NSCLC).



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x